Alcon Reports Q2 2025 EPS Beat, $2.58 Billion Revenue; Launches Tryptyr, Acquires STAAR Surgical Amid Tariff Pressures

Alcon reported its second-quarter 2025 financial results, posting adjusted earnings per share of $0.76, beating estimates by $0.04, and revenue of $2.58 billion, slightly below the expected $2.62 billion but representing a 3.8% year-over-year increase. The company recorded net income of $175 million. Alcon lowered its full-year 2025 revenue outlook due to ongoing U.S. tariff pressures estimated to impact sales by $100 million, but reaffirmed its earnings per share guidance in the range of $3.05 to $3.15. Operational changes are expected to help offset the tariff impact. During the quarter, Alcon launched a new product, Tryptyr, and announced the acquisition of STAAR Surgical. Separately, Vivos Therapeutics reported second-quarter 2025 financial results with $3.8 million in revenue, $2.1 million in gross profit, and a $4.9 million operating loss. The company also completed the acquisition of the Sleep Center of Nevada to expand its obstructive sleep apnea treatment offerings. Additionally, OS Therapies and HCW Biologics released their second-quarter 2025 financial results, and ATRENEW Inc. announced unaudited financial results for the same period.